NCT07209813View on ClinicalTrials.gov

GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 12, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

GKL-006

GKL-006（3.0±0.9）×108 iNKT cells/m2 IV single infusion on Day 1 of each 14-day cycle for up to 11 cycles (≈6 month) in the absence of disease progression or unacceptable toxicity.

All Listed Sponsors
lead

Beijing Gene Key Life Technology Co., Ltd

INDUSTRY